Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 1999

View Archived Issues

New approach to inhibiting thrombin-induced neuronal cell death

Vagus nerve stimulation offers new possibilities for the treatment of depression

Preliminary results reported for Biojector 2000-delivered malaria vaccine

Biomira's BLP25 liposome technology offers promise as cancer therapy

MGH team identifies TSP-2 as a novel endogenous antiangiogenic factor

Immune Network Research reacquires 1F7 AIDS antibody

Genome Therapeutics initiates osteoporosis genomics alliance with Wyeth-Ayerst

Millennium validates prostate cancer gene target as part of Lilly collaboration

NPS and Allelix finalize merger

Nycomed Amersham files for E.U. approval of ultrasound imaging agent

Schwarz adds new anticonvulsant to R&D portfolio

Impressive early phase II clinical data reported for OvaRex in relapsed ovarian cancer

Cel-Sci completes another study in head and neck cancer

BIM-46068: a pseudopeptide FTase inhibitor with promise for cancer Rx

Interneuron licenses worldwide rights to pagoclone to Warner-Lambert

Salix responds to FDA approvable letter and reacquires rights to UC treatment from AstraZeneca

Agents for accelerating peristalsis in development at Dainippon

New series of selectin inhibitors patented by Sumitomo

Mitsui presents differentiation-inducing agents

ADIR discloses new melatonergic agents with cyclic structure

Antiangiogenic fumagillin analogues in the pipeline at BioChem Pharma

BMS presents new water-soluble triazole antifungal prodrugs with superior properties

Pharmacological profile of SR-141716A, a selective CB1 antagonist, further characterized

Citicoline Stroke Study Group trial does not show benefit for citicoline in overall study population

Aventis receives first product approval: E.U. grants approval of Synercid

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.